Ratings by Barclays (Peter Lawson)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/9/2026 | Nuvalent | NUVL | Downgrade | Equalweight (Overweight) |
88.49 (123.44) |
39.5% | Details | |
| 5/20/2026 | Relay Therapeutics | RLAY | Maintain | Overweight (N/A) |
|
Details | ||
| 5/7/2026 | BeOne Medicines | ONC | Maintain | Overweight (N/A) |
|
Details | ||
| 5/1/2026 | Syndax Pharmaceuticals | SNDX | Maintain | Overweight (N/A) |
|
Details | ||
| 4/8/2026 | Relay Therapeutics | RLAY | Maintain | Overweight (N/A) |
|
Details | ||
| 2/27/2026 | BeOne Medicines | ONC | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/25/2026 | Iovanace Biotherapeutics | IOVA | Maintain | Overweight (N/A) |
|
Details | ||
| 2/18/2026 | Incyte | INCY | Maintain | Overweight (N/A) |
|
Details | ||
| 2/4/2026 | Incyte | INCY | Maintain | Overweight (N/A) |
|
Details | ||
| 2/4/2026 | BeOne Medicines | ONC | Maintain | Overweight (N/A) |
|
Details | ||
| 12/17/2025 | Iovanace Biotherapeutics | IOVA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/24/2025 | Syndax Pharmaceuticals | SNDX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/24/2025 | Kura Oncology | KURA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/24/2025 | Iovanace Biotherapeutics | IOVA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/24/2025 | Incyte | INCY | Maintain | Overweight (N/A) |
|
Details | ||
| 11/18/2025 | Nuvalent | NUVL | Maintain | Overweight (N/A) |
|
Details | ||
| 11/4/2025 | Syndax Pharmaceuticals | SNDX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/31/2025 | Nuvalent | NUVL | Maintain | Overweight (N/A) |
|
Details | ||
| 10/29/2025 | Incyte | INCY | Maintain | Overweight (N/A) |
|
Details | ||
| 9/18/2025 | BeOne Medicines | ONC | New Coverage | Overweight (N/A) |
327.20 (276.13) |
-15.61% | Details | |
| 9/4/2025 | Ideaya Biosciences | IDYA | New Coverage | Overweight (N/A) |
25.48 (34.91) |
37.01% | Details | |
| 8/14/2025 | Schrodinger | SDGR | New Coverage | Overweight (N/A) |
18.85 (15.04) |
-20.21% | Details | |
| 8/1/2025 | Incyte | INCY | New Coverage | Overweight (N/A) |
77.55 (104.40) |
34.62% | Details | |
| 7/23/2025 | Replimune Group | REPL | Downgrade | Equalweight (Overweight) |
12.32 (11.42) |
-7.31% | Details | |
| 7/22/2025 | Replimune Group | REPL | Maintain | Overweight (N/A) |
|
Details | ||
| 7/10/2025 | Exelixis | EXEL | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/14/2025 | Karyopharm Therapeutics | KPTI | Maintain | Overweight (N/A) |
|
Details | ||
| 5/12/2025 | Iovanace Biotherapeutics | IOVA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/8/2025 | Xencor, Inc. | XNCR | Maintain | Underweight (N/A) |
|
Details | ||
| 5/7/2025 | Immunocore Holdings | IMCR | Maintain | (N/A) |
|
Details | ||
| 5/2/2025 | Kura Oncology | KURA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/2/2025 | Bicycle Therapeutics | BCYC | Maintain | Overweight (N/A) |
|
Details | ||
| 5/2/2025 | Arvinas Inc. | ARVN | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/28/2025 | Spring Works Therapeutics | SWTX | Downgrade | Equalweight (Overweight) |
44.72 (46.99) |
5.08% | Details | |
| 4/22/2025 | Spring Works Therapeutics | SWTX | Maintain | Overweight (N/A) |
|
Details | ||
| 4/14/2025 | Iovanace Biotherapeutics | IOVA | Maintain | Overweight (N/A) |
|
Details | ||
| 4/11/2025 | Syndax Pharmaceuticals | SNDX | Maintain | Overweight (N/A) |
|
Details | ||
| 4/2/2025 | Biomea Fusion Inc. | BMEA | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/7/2025 | Tscan Therapeutics Inc | TCRX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/26/2025 | Geron Corporation | GERN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/13/2025 | Exelixis | EXEL | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/3/2025 | Arvinas Inc. | ARVN | Maintain | Overweight (N/A) |
|
Details | ||
| 1/21/2025 | Replimune Group | REPL | Maintain | Overweight (N/A) |
|
Details | ||
| 11/7/2024 | Revolution | RVMD | Maintain | Overweight (N/A) |
|
Details | ||
| 10/30/2024 | Biomea Fusion Inc. | BMEA | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/28/2024 | Prelude Therapeutics | PRLD | Maintain | Underweight (N/A) |
|
Details | ||
| 10/25/2024 | Arcus Biosciences | RCUS | Maintain | Overweight (N/A) |
|
Details | ||
| 9/27/2024 | Revolution | RVMD | Maintain | Overweight (N/A) |
|
Details | ||
| 9/27/2024 | Biomea Fusion Inc. | BMEA | Maintain | Equalweight (N/A) |
|
Details | ||
| 9/9/2024 | Relay Therapeutics | RLAY | Maintain | Overweight (N/A) |
|
Details | ||
| 9/9/2024 | Xencor, Inc. | XNCR | Maintain | Underweight (N/A) |
|
Details | ||
| 9/6/2024 | Nuvalent | NUVL | Maintain | Overweight (N/A) |
|
Details | ||
| 8/29/2024 | Nuvalent | NUVL | New Coverage | Overweight (N/A) |
84.28 (88.49) |
5% | Details | |
| 8/15/2024 | Syndax Pharmaceuticals | SNDX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/13/2024 | Exscientia PLC | EXAI | Downgrade | Equalweight (Overweight) |
4.86 (4.84) |
-0.41% | Details | |
| 8/9/2024 | Immunocore Holdings | IMCR | Maintain | Overweight (N/A) |
|
Details | ||
| 7/31/2024 | MacroGenics | MGNX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/31/2024 | Arvinas Inc. | ARVN | Maintain | Overweight (N/A) |
|
Details | ||
| 7/29/2024 | MacroGenics | MGNX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/29/2024 | Blueprint Medicines | BPMC | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/26/2024 | Relay Therapeutics | RLAY | Maintain | Overweight (N/A) |
|
Details | ||
| 7/18/2024 | Revolution | RVMD | Maintain | Overweight (N/A) |
|
Details | ||
| 7/15/2024 | Nurix | NRIX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/12/2024 | Revolution | RVMD | New Coverage | Overweight (N/A) |
42.46 (169.51) |
299.22% | Details | |
| 7/8/2024 | Arcus Biosciences | RCUS | Maintain | Overweight (N/A) |
|
Details | ||
| 7/2/2024 | Spring Works Therapeutics | SWTX | Maintain | Overweight (N/A) |
|
Details | ||
| 6/20/2024 | Prelude Therapeutics | PRLD | Downgrade | Underweight (Equalweight) |
3.93 (4.38) |
11.45% | Details | |
| 6/7/2024 | Replimune Group | REPL | Maintain | Overweight (N/A) |
|
Details | ||
| 6/7/2024 | Biomea Fusion Inc. | BMEA | Downgrade | Equalweight (Overweight) |
11.84 (1.23) |
-89.61% | Details | |
| 6/4/2024 | Replimune Group | REPL | Maintain | Overweight (N/A) |
|
Details | ||
| 6/4/2024 | Arcus Biosciences | RCUS | Maintain | Overweight (N/A) |
|
Details | ||
| 5/24/2024 | Tango Therapeutics Inc. | TNGX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/16/2024 | Adaptimmune Therapeutics plc | ADAP | Maintain | Underweight (N/A) |
|
Details | ||
| 5/14/2024 | Tscan Therapeutics Inc | TCRX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/10/2024 | MacroGenics | MGNX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/10/2024 | Relay Therapeutics | RLAY | Upgrade | Overweight (Equalweight) |
6.51 (17.44) |
167.9% | Details | |
| 5/3/2024 | Blueprint Medicines | BPMC | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/30/2024 | Deciphera | DCPH | Upgrade | Equalweight (Underweight) |
14.65 (25.59) |
74.68% | Details | |
| 4/11/2024 | Exelixis | EXEL | Downgrade | Equalweight (Overweight) |
23.72 (51.34) |
116.44% | Details | |
| 2/29/2024 | Spring Works Therapeutics | SWTX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/29/2024 | MacroGenics | MGNX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/29/2024 | Iovanace Biotherapeutics | IOVA | Maintain | Overweight (N/A) |
|
Details | ||
| 2/29/2024 | Arvinas Inc. | ARVN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/27/2024 | Fate Therapeutics | FATE | Maintain | Overweight (N/A) |
|
Details | ||
| 2/13/2024 | Blueprint Medicines | BPMC | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/1/2024 | Kura Oncology | KURA | Maintain | Overweight (N/A) |
|
Details | ||
| 1/30/2024 | Exelixis | EXEL | Maintain | Overweight (N/A) |
|
Details | ||
| 1/25/2024 | Spring Works Therapeutics | SWTX | Maintain | Overweight (N/A) |
|
Details | ||
| 12/6/2023 | Replimune Group | REPL | Maintain | Overweight (N/A) |
|
Details | ||
| 12/4/2023 | Immunogen Inc. | IMGN | Downgrade | Equalweight (Overweight) |
29.35 (31.25) |
6.47% | Details | |
| 12/1/2023 | Immunogen Inc. | IMGN | Downgrade | Equalweight (Overweight) |
29.35 (31.25) |
6.47% | Details | |
| 10/31/2023 | Biomea Fusion Inc. | BMEA | Maintain | Overweight (N/A) |
|
Details | ||
| 10/27/2023 | Blueprint Medicines | BPMC | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/24/2023 | Arvinas Inc. | ARVN | Maintain | Overweight (N/A) |
|
Details | ||
| 9/18/2023 | Iovanace Biotherapeutics | IOVA | Maintain | Overweight (N/A) |
|
Details | ||
| 8/9/2023 | Arvinas Inc. | ARVN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/4/2023 | Prelude Therapeutics | PRLD | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/3/2023 | Exelixis | EXEL | Maintain | Overweight (N/A) |
|
Details | ||
| 8/2/2023 | Immunogen Inc. | IMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 7/26/2023 | Syndax Pharmaceuticals | SNDX | Maintain | Overweight (N/A) |
|
Details | ||
| 6/26/2023 | Biomea Fusion Inc. | BMEA | Maintain | Overweight (N/A) |
|
Details | ||
| 6/12/2023 | Immunogen Inc. | IMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 6/9/2023 | Immunogen Inc. | IMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 5/23/2023 | Blueprint Medicines | BPMC | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/12/2023 | Biomea Fusion Inc. | BMEA | New Coverage | Overweight (N/A) |
32.98 (11.84) |
-64.1% | Details | |
| 4/28/2023 | Spring Works Therapeutics | SWTX | Maintain | Overweight (N/A) |
|
Details | ||
| 4/19/2023 | Relay Therapeutics | RLAY | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/9/2023 | Nurix | NRIX | New Coverage | Overweight (N/A) |
9.09 (18.86) |
107.48% | Details | |
| 1/23/2023 | Blueprint Medicines | BPMC | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/5/2023 | Fate Therapeutics | FATE | Maintain | Overweight (N/A) |
|
Details | ||
| 1/5/2023 | Blueprint Medicines | BPMC | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/4/2023 | Deciphera | DCPH | Maintain | Underweight (N/A) |
|
Details | ||
| 12/21/2022 | Arcus Biosciences | RCUS | Maintain | Overweight (N/A) |
|
Details | ||
| 12/12/2022 | Blueprint Medicines | BPMC | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/30/2022 | Immunocore Holdings | IMCR | New Coverage | Overweight (N/A) |
58.95 (29.20) |
-50.47% | Details | |
| 11/23/2022 | Arvinas Inc. | ARVN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/15/2022 | Immunogen Inc. | IMGN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/2/2022 | Exelixis | EXEL | Maintain | Overweight (N/A) |
|
Details | ||
| 11/2/2022 | Blueprint Medicines | BPMC | Maintain | Equalweight (N/A) |
|
Details | ||
| 9/30/2022 | Relay Therapeutics | RLAY | New Coverage | Equalweight (N/A) |
24.12 (17.44) |
-27.69% | Details | |
| 9/9/2022 | Immunogen Inc. | IMGN | New Coverage | Overweight (N/A) |
5.36 (31.25) |
483.02% | Details | |
| 9/9/2022 | Arvinas Inc. | ARVN | New Coverage | Overweight (N/A) |
45.36 (8.14) |
-82.05% | Details | |
| 8/9/2022 | MacroGenics | MGNX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/5/2022 | Karyopharm Therapeutics | KPTI | Maintain | Overweight (N/A) |
|
Details | ||
| 7/28/2022 | Bicycle Therapeutics | BCYC | New Coverage | Overweight (N/A) |
22.20 (4.00) |
-81.98% | Details | |
| 7/7/2022 | CytomX Therapeutics | CTMX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/28/2022 | Deciphera | DCPH | Downgrade | Underweight (Equalweight) |
8.18 (25.59) |
212.84% | Details | |
| 2/28/2022 | Prelude Therapeutics | PRLD | Downgrade | Equalweight (Overweight) |
10.60 (3.93) |
-62.92% | Details | |
| 1/18/2022 | CytomX Therapeutics | CTMX | Upgrade | Overweight (Underweight) |
3.95 (3.15) |
-20.25% | Details | |
| 11/19/2021 | Arcus Biosciences | RCUS | Maintain | Overweight (N/A) |
|
Details | ||
| 11/17/2021 | Prelude Therapeutics | PRLD | Maintain | Overweight (N/A) |
|
Details | ||
| 11/9/2021 | Arcus Biosciences | RCUS | Maintain | Overweight (N/A) |
|
Details | ||
| 11/8/2021 | Deciphera | DCPH | Downgrade | Equalweight (Overweight) |
36.00 (25.59) |
-28.92% | Details | |
| 5/28/2021 | Adaptimmune Therapeutics plc | ADAP | New Coverage | Underweight (N/A) |
4.98 (0.05) |
-99% | Details | |
| 5/28/2021 | CytomX Therapeutics | CTMX | Downgrade | Underweight (Equalweight) |
8.22 (3.15) |
-61.68% | Details | |
| 5/19/2021 | Iovanace Biotherapeutics | IOVA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/5/2021 | Deciphera | DCPH | Maintain | Overweight (N/A) |
|
Details | ||
| 4/30/2021 | Agios Pharma | AGIO | Maintain | Overweight (N/A) |
|
Details | ||
| 3/12/2021 | MacroGenics | MGNX | Upgrade | Overweight (Underweight) |
27.63 (4.69) |
-83.03% | Details | |
| 2/26/2021 | Spring Works Therapeutics | SWTX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/25/2021 | Arcus Biosciences | RCUS | Maintain | Overweight (N/A) |
|
Details | ||
| 2/24/2021 | Xencor, Inc. | XNCR | Maintain | Underweight (N/A) |
|
Details | ||
| 2/18/2021 | Blueprint Medicines | BPMC | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/12/2021 | Karyopharm Therapeutics | KPTI | Maintain | Overweight (N/A) |
|
Details | ||
| 2/10/2021 | Deciphera | DCPH | Maintain | Overweight (N/A) |
|
Details | ||
| 1/27/2021 | Agios Pharma | AGIO | Maintain | Overweight (N/A) |
|
Details | ||
| 1/15/2021 | Fate Therapeutics | FATE | Maintain | Overweight (N/A) |
|
Details | ||
| 12/17/2020 | Y-mAbs Therapeutics | YMAB | Maintain | Overweight (N/A) |
|
Details | ||
| 12/17/2020 | Spring Works Therapeutics | SWTX | Maintain | (N/A) |
|
Details | ||
| 12/17/2020 | MacroGenics | MGNX | Maintain | Underweight (N/A) |
|
Details | ||
| 12/17/2020 | Iovanace Biotherapeutics | IOVA | Maintain | Overweight (N/A) |
|
Details | ||
| 12/17/2020 | Fate Therapeutics | FATE | Maintain | Overweight (N/A) |
|
Details | ||
| 12/7/2020 | Syndax Pharmaceuticals | SNDX | Maintain | Overweight (N/A) |
|
Details | ||
| 12/7/2020 | Kura Oncology | KURA | Maintain | Overweight (N/A) |
|
Details | ||
| 12/7/2020 | Fate Therapeutics | FATE | Maintain | Overweight (N/A) |
|
Details | ||
| 12/2/2020 | Fate Therapeutics | FATE | Maintain | Overweight (N/A) |
|
Details | ||
| 11/19/2020 | Syndax Pharmaceuticals | SNDX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/12/2020 | Xencor, Inc. | XNCR | Maintain | Underweight (N/A) |
|
Details | ||
| 11/9/2020 | Y-mAbs Therapeutics | YMAB | Maintain | Overweight (N/A) |
|
Details | ||
| 11/9/2020 | Epizyme | EPZM | Maintain | Overweight (N/A) |
|
Details | ||
| 11/9/2020 | CytomX Therapeutics | CTMX | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/6/2020 | Iovanace Biotherapeutics | IOVA | Maintain | Overweight (N/A) |
|
Details | ||
| 10/22/2020 | Agios Pharma | AGIO | Upgrade | Overweight (Equalweight) |
35.39 (35.59) |
0.57% | Details | |
| 10/7/2020 | Y-mAbs Therapeutics | YMAB | Maintain | Overweight (N/A) |
|
Details | ||
| 10/6/2020 | Iovanace Biotherapeutics | IOVA | Maintain | Overweight (N/A) |
|
Details | ||
| 9/30/2020 | Kura Oncology | KURA | Maintain | Overweight (N/A) |
|
Details | ||
| 9/23/2020 | Blueprint Medicines | BPMC | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/31/2020 | Kura Oncology | KURA | Maintain | Overweight (N/A) |
|
Details | ||
| 8/13/2020 | Spring Works Therapeutics | SWTX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/6/2020 | Immunomedics | IMMU | Maintain | Overweight (N/A) |
|
Details | ||
| 6/23/2020 | Karyopharm Therapeutics | KPTI | Maintain | Overweight (N/A) |
|
Details | ||
| 6/8/2020 | Y-mAbs Therapeutics | YMAB | Maintain | (N/A) |
|
Details | ||
| 6/4/2020 | Replimune Group | REPL | Maintain | Overweight (N/A) |
|
Details | ||
| 5/22/2020 | Syndax Pharmaceuticals | SNDX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/18/2020 | Deciphera | DCPH | Maintain | Overweight (N/A) |
|
Details | ||
| 5/8/2020 | CytomX Therapeutics | CTMX | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/5/2020 | Immunomedics | IMMU | New Coverage | Overweight (N/A) |
30.38 (87.86) |
189.2% | Details | |
| 5/5/2020 | Y-mAbs Therapeutics | YMAB | New Coverage | Overweight (N/A) |
32.39 (8.61) |
-73.42% | Details | |
| 5/5/2020 | Blueprint Medicines | BPMC | New Coverage | Equalweight (N/A) |
57.15 (129.46) |
126.53% | Details | |
| 5/5/2020 | Replimune Group | REPL | New Coverage | Overweight (N/A) |
16.21 (12.32) |
-24% | Details | |
| 5/5/2020 | Kura Oncology | KURA | New Coverage | Overweight (N/A) |
13.88 (10.38) |
-25.22% | Details | |
| 5/5/2020 | Spring Works Therapeutics | SWTX | New Coverage | Overweight (N/A) |
30.21 (44.72) |
48.03% | Details | |
| 5/1/2020 | Agios Pharma | AGIO | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/4/2020 | CytomX Therapeutics | CTMX | New Coverage | Equalweight (N/A) |
7.30 (3.15) |
-56.85% | Details | |
| 3/4/2020 | Karyopharm Therapeutics | KPTI | New Coverage | Overweight (N/A) |
27.72 (9.65) |
-65.19% | Details | |
| 3/4/2020 | Fate Therapeutics | FATE | New Coverage | Overweight (N/A) |
31.01 (2.16) |
-93.03% | Details | |
| 3/4/2020 | Arcus Biosciences | RCUS | New Coverage | Overweight (N/A) |
17.59 (28.18) |
60.2% | Details | |
| 3/4/2020 | Deciphera | DCPH | New Coverage | Overweight (N/A) |
57.02 (25.59) |
-55.12% | Details | |
| 3/4/2020 | Exelixis | EXEL | New Coverage | Overweight (N/A) |
19.29 (51.34) |
166.15% | Details | |
| 3/4/2020 | Syndax Pharmaceuticals | SNDX | New Coverage | Overweight (N/A) |
9.80 (19.61) |
100.1% | Details | |
| 3/4/2020 | MacroGenics | MGNX | New Coverage | Underweight (N/A) |
8.89 (4.69) |
-47.24% | Details | |
| 3/4/2020 | Agios Pharma | AGIO | New Coverage | Equalweight (N/A) |
49.34 (35.59) |
-27.87% | Details | |
| 3/4/2020 | Iovanace Biotherapeutics | IOVA | New Coverage | Overweight (N/A) |
35.99 (4.44) |
-87.66% | Details | |
| 3/4/2020 | Nektar Therapeutics | NKTR | New Coverage | Overweight (N/A) |
20.10 (66.69) |
231.79% | Details | |
| 3/4/2020 | Xencor, Inc. | XNCR | New Coverage | Underweight (N/A) |
32.28 (14.08) |
-56.38% | Details | |
| 3/4/2020 | Epizyme | EPZM | New Coverage | Overweight (N/A) |
22.99 (1.47) |
-93.61% | Details |
